Answers are grounded in this paper and cite their sources.
T cells spared by fratricide. They also showed strong anti-leukemic activity in cell line- and patient-derived T-ALL xenografts. The strategy described in this study fits well with existing clinical-grade cell manufacturing processes and can be rapidly implemented for the treatment of patients with high-risk T-cell malignancies.
No takes yet. Share an insight, caveat, or question.
Png et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: